On this page
Research Article | Open Access
Volume 14 2022 | None
A cross sectional study to assess the levels of serum FGF-23 in patients with type 2 diabetes mellitus with and without hypertension
Menaha.R, Sowndharya.J, Vijayapriya.I, Ganesan.G, Balasubramanian.S, Yuvaraj.R
Pages: 1977-1989
Introduction: People with diabetes mellitus are known to have endothelial dysfunction and are at a higher risk of atherosclerotic cardiovascular disease (ASCVD)Fibroblast growth factor – 23 (FGF-23) is a hormone produced in bones and it primarily acts on kidneys to increase the urinary phosphate excretion Aim: To assess the levels of serum fibroblast Growth factor-23 (FGF-23) in patients with type 2 diabetes mellitus with hypertension and without hypertension Materials and Methods: This study was an institution based observational prospective case-control study. The subjects were divided into 2 groups such as patients with Type 2 DM with HTN & without HTN. After obtaining Institutional Ethics Clearance, the anthropometric measurements, BP, glycaemic parameters, lipid parameters & renal parameters were estimated along with serum FGF-23 levels among the study group. Statistical analysis was done with SPSS version 21.0. Result & Conclusion: Based on the findings of this observational prospective case-control study we can conclude that FGF-23 levels are significantly elevated in patients with type 2 diabetes mellitus with hypertension when compared to diabetes group alone. Assessment of FGF-23 can be used as a surrogate marker for early detection of atherosclerotic vascular disease and also for estimation of cardiovascular risk.
Diabetes Mellitus, Hypertension, Fibroblast Growth Factor-23, Serum cholesterol, glucaemic index